Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1991 Mar;46(3):184–189. doi: 10.1136/thx.46.3.184

Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.

K P Hui 1, I K Taylor 1, G W Taylor 1, P Rubin 1, J Kesterson 1, N C Barnes 1, P J Barnes 1
PMCID: PMC463027  PMID: 1851340

Abstract

The effect of a single oral dose (800 mg) of zileuton (A-64077), a specific 5-lipoxygenase inhibitor, on the early and late airway responses to inhaled allergen was studied in a randomised, double blind, placebo controlled, and crossover trial in nine subjects with atopic asthma. Leukotriene generation was also assessed in vivo by measuring urinary leukotriene (LT) E4 excretion, and ex vivo by measuring calcium ionophore stimulated whole blood LTB4 production. Zileuton almost completely inhibited ex vivo LTB4 production but reduced urinary excretion of LTE4 by only about half. There was a trend for the early asthmatic response to be less on the day of zileuton treatment, but this did not reach statistical significance (p = 0.08). The zileuton induced reduction in maximum fall in FEV1 in the early asthmatic response was, however, significantly related to the reduction in urinary LTE4 excretion (r = 0.8), but not to the reduction in LTB4 generation ex vivo. There was no significant change in the allergen induced late asthmatic response, or in the increase in airway responsiveness to methacholine following antigen. The results provide some support for the hypothesis that the cysteinyl leukotrienes have a role in the allergen induced early asthmatic response. More complete in vivo inhibition of 5-lipoxygenase may be needed to produce a significant reduction in airway response to allergen challenge.

Full text

PDF
185

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelroth E., Morris M. M., Hargreave F. E., O'Byrne P. M. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986 Aug 21;315(8):480–484. doi: 10.1056/NEJM198608213150803. [DOI] [PubMed] [Google Scholar]
  2. Arm J. P., Spur B. W., Lee T. H. The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol. 1988 Oct;82(4):654–660. doi: 10.1016/0091-6749(88)90979-7. [DOI] [PubMed] [Google Scholar]
  3. Barnes N. C., Piper P. J., Costello J. F. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax. 1984 Jul;39(7):500–504. doi: 10.1136/thx.39.7.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bray M. A. The pharmacology and pathophysiology of leukotriene B4. Br Med Bull. 1983 Jul;39(3):249–254. doi: 10.1093/oxfordjournals.bmb.a071828. [DOI] [PubMed] [Google Scholar]
  5. Chan-Yeung M., Chan H., Tse K. S., Salari H., Lam S. Histamine and leukotrienes release in bronchoalveolar fluid during plicatic acid-induced bronchoconstriction. J Allergy Clin Immunol. 1989 Nov;84(5 Pt 1):762–768. doi: 10.1016/0091-6749(89)90306-0. [DOI] [PubMed] [Google Scholar]
  6. Cockcroft D. W., Killian D. N., Mellon J. J., Hargreave F. E. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy. 1977 May;7(3):235–243. doi: 10.1111/j.1365-2222.1977.tb01448.x. [DOI] [PubMed] [Google Scholar]
  7. Dahlén S. E., Hedqvist P., Hammarström S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980 Dec 4;288(5790):484–486. doi: 10.1038/288484a0. [DOI] [PubMed] [Google Scholar]
  8. Davidson A. B., Lee T. H., Scanlon P. D., Solway J., McFadden E. R., Jr, Ingram R. H., Jr, Corey E. J., Austen K. F., Drazen J. M. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis. 1987 Feb;135(2):333–337. doi: 10.1164/arrd.1987.135.2.333. [DOI] [PubMed] [Google Scholar]
  9. Diaz P., Gonzalez M. C., Galleguillos F. R., Ancic P., Cromwell O., Shepherd D., Durham S. R., Gleich G. J., Kay A. B. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. Am Rev Respir Dis. 1989 Jun;139(6):1383–1389. doi: 10.1164/ajrccm/139.6.1383. [DOI] [PubMed] [Google Scholar]
  10. Drazen J. M., Austen K. F. Leukotrienes and airway responses. Am Rev Respir Dis. 1987 Oct;136(4):985–998. doi: 10.1164/ajrccm/136.4.985. [DOI] [PubMed] [Google Scholar]
  11. Ford-Hutchinson A. W., Bray M. A., Doig M. V., Shipley M. E., Smith M. J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980 Jul 17;286(5770):264–265. doi: 10.1038/286264a0. [DOI] [PubMed] [Google Scholar]
  12. Fuller R. W., Black P. N., Dollery C. T. Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J Allergy Clin Immunol. 1989 May;83(5):939–944. doi: 10.1016/0091-6749(89)90109-7. [DOI] [PubMed] [Google Scholar]
  13. Fuller R. W., Maltby N., Richmond R., Dollery C. T., Taylor G. W., Ritter W., Philipp E. Oral nafazatrom in man: effect on inhaled antigen challenge. Br J Clin Pharmacol. 1987 Jun;23(6):677–681. doi: 10.1111/j.1365-2125.1987.tb03101.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hammarström S. Leukotrienes. Annu Rev Biochem. 1983;52:355–377. doi: 10.1146/annurev.bi.52.070183.002035. [DOI] [PubMed] [Google Scholar]
  15. Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979 Jul;8(1):7–20. doi: 10.1111/j.1365-2125.1979.tb05903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Israel E., Juniper E. F., Callaghan J. T., Mathur P. N., Morris M. M., Dowell A. R., Enas G. G., Hargreave F. E., Drazen J. M. Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis. 1989 Nov;140(5):1348–1353. doi: 10.1164/ajrccm/140.5.1348. [DOI] [PubMed] [Google Scholar]
  17. Johnson H. G., Stout B. K. Activity of a novel hydroquinone inhibitor of leukotriene synthesis (U-66,858) in the rhesus monkey Ascaris reactor. Int Arch Allergy Appl Immunol. 1988;87(2):204–207. doi: 10.1159/000234673. [DOI] [PubMed] [Google Scholar]
  18. Kreutner W., Sherwood J., Sehring S., Rizzo C., Chapman R. W., Siegel M. I., Egan R. W. Antiallergy activity of Sch 37224, a new inhibitor of leukotriene formation. J Pharmacol Exp Ther. 1988 Dec;247(3):997–1003. [PubMed] [Google Scholar]
  19. Ku E. C., Raychaudhuri A., Ghai G., Kimble E. F., Lee W. H., Colombo C., Dotson R., Oglesby T. D., Wasley J. W. Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models. Biochim Biophys Acta. 1988 Apr 15;959(3):332–342. doi: 10.1016/0005-2760(88)90207-x. [DOI] [PubMed] [Google Scholar]
  20. Mann J. S., Robinson C., Sheridan A. Q., Clement P., Bach M. K., Holgate S. T. Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma. Thorax. 1986 Oct;41(10):746–752. doi: 10.1136/thx.41.10.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Marom Z., Shelhamer J. H., Bach M. K., Morton D. R., Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982 Sep;126(3):449–451. doi: 10.1164/arrd.1982.126.3.449. [DOI] [PubMed] [Google Scholar]
  22. Rafferty P., Ng W. H., Phillips G., Clough J., Church M. K., Aurich R., Ollier S., Holgate S. T. The inhibitory actions of azelastine hydrochloride on the early and late bronchoconstrictor responses to inhaled allergen in atopic asthma. J Allergy Clin Immunol. 1989 Nov;84(5 Pt 1):649–657. doi: 10.1016/0091-6749(89)90292-3. [DOI] [PubMed] [Google Scholar]
  23. Richmond R., Turner N. C., Maltby N., Heavey D., Vial J., Dollery C. T., Taylor G. W. Single-step procedure for the extraction and purification of leukotrienes B4, C4 and D4. J Chromatogr. 1987 Jul 3;417(2):241–251. doi: 10.1016/0378-4347(87)80117-2. [DOI] [PubMed] [Google Scholar]
  24. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983 May 6;220(4597):568–575. doi: 10.1126/science.6301011. [DOI] [PubMed] [Google Scholar]
  25. Summers J. B., Gunn B. P., Martin J. G., Martin M. B., Mazdiyasni H., Stewart A. O., Young P. R., Bouska J. B., Goetze A. M., Dyer R. D. Structure-activity analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis. J Med Chem. 1988 Oct;31(10):1960–1964. doi: 10.1021/jm00118a016. [DOI] [PubMed] [Google Scholar]
  26. Taylor G. W., Taylor I., Black P., Maltby N. H., Turner N., Fuller R. W., Dollery C. T. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. doi: 10.1016/s0140-6736(89)91611-5. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES